Using engineered T regulatory cells to improve pancreatic beta cell health in Type 1 diabetes
Harnessing engineered T regulatory cells to promote beta cell health in T1D
This study is exploring a new way to help people with Type 1 diabetes by creating special immune cells that can protect the insulin-producing cells in the pancreas, aiming to improve their health and function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11041067 on NIH RePORTER |
What this research studies
This research focuses on Type 1 diabetes (T1D), a condition where the body's immune system attacks insulin-producing beta cells in the pancreas. The project aims to develop engineered T regulatory cells (EngTregs) that can specifically target and suppress the autoimmune response against these beta cells. By utilizing advanced gene editing techniques, the researchers will create Tregs that can home in on the pancreatic islet and help restore beta cell function and health. This innovative approach seeks to reduce inflammation and promote the survival and growth of beta cells, potentially leading to better management of T1D.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Type 1 diabetes, particularly those experiencing beta cell stress and dysfunction.
Not a fit: Patients with Type 2 diabetes or other forms of diabetes unrelated to autoimmune destruction of beta cells may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that restore beta cell function and improve the lives of individuals with Type 1 diabetes.
How similar studies have performed: While the approach of using engineered T regulatory cells is innovative, similar strategies targeting autoimmune conditions have shown promise in preliminary studies, suggesting potential for success.
Where this research is happening
Seattle, United States
- Benaroya Research Inst at Virginia Mason — Seattle, United States (Active)
Researchers
- Principal investigator: Buckner, Jane Hoyt — Benaroya Research Inst at Virginia Mason
- Study coordinator: Buckner, Jane Hoyt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.